Compare Dollar Tree, Inc. (DLTR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Dollar Tree, Inc. trades at $117.94 (market cap $22.26B), while Zimmer Biomet Holdings Inc trades at $89.4 (market cap $16.95B). The key difference: Dollar Tree, Inc. is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| DLTR | ZBH | |
|---|---|---|
Market Cap | $22.26B | $16.95B |
Volume | 2,317,428 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $103.98 |
52-Week Low | $86.80 | $79.58 |
Typical Hold Time | 58 Days | 89 Days |
Enterprise Value | $28.87B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $116.30, up 0.09% with a bullish technical signal despite bearish moving averages. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $2.70 beating expectations of $1.15. Revenue trends show recovery from 2025's $17.58B to projected $20.1B in 2026, while net income rebounds from -$3.03B to projected $1.6B. Analyst consensus is bullish with 53% buy ratings and $139.33 price target, representing 20% upside potential.
DLTR presents a compelling investment case with improving fundamentals and positive earnings momentum, though margin pressures and tariff volatility remain key risks. The stock's attractive valuation (P/E 14.54, EV/EBITDA 9.91) combined with strategic initiatives and store expansions support growth outlook, but investors should monitor cost inflation and competitive pressures in the discount retail sector.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
